The usefulness of the nitrate reductase assay for detecting drug-resistant Mycobacterium tuberculosis
Abstract
Introduction: The early detection of resistance in Mycobacterium tuberculosis is of primary importance for both patient management and infection control.
Objective: To evaluate nitrate reductase assay (NRA) performance for the testing of Mycobacterium tuberculosis drug-resistance against first-line anti-tuberculosis drugs, such as rifampicin (RIF), isoniazid (INH), streptomycin (STR) and ethambutol (EMB).
Materials and methods: Fifty isolates were tested by using both the proportion method and the nitrate reductase assay.
Results: RIF, INH, STR and EMB sensitivity was found to be 92%, 91%, 63% and 80% and 100%, respectively, and a corresponding specificity of 100%, 100%, 100% and 98% by comparing NRA results to those obtained with the gold standard (i.e., the proportion method). The positive predictive values for RIF, INH, STR and EMB were 100%, 100%, 100% and 80% and the negative predictive values were 97%, 93%, 73% and 98%, respectively. The mean time for obtaining results was shorter when using the nitrate reductase assay (10 days) compared to using the proportion method (28 days). Excellent agreement was observed between both phenotypic tests: 98%, 96%, 81% and 96% for RIF, INH, STR and EMB, respectively.
Conclusions: The results showed that the nitrate reductase assay is suitable for the early determination of multidrug-resistant tuberculosis (MDR-TB) and is a useful tool for the quick and accurate determination of a rapid M. tuberculosis drug-sensitivity test in countries having low resources.
Downloads
Some similar items:
- Juan Gabriel Bueno-Sánchez, Jairo René Martínez-Morales, Elena E. Stashenko, Wellman Ribón, Anti-tubercular activity of eleven aromatic and medicinal plants occurring in Colombia , Biomedica: Vol. 29 No. 1 (2009)
- María Consuelo Garzón, Dailyn Yorledy Angée, Claudia Llerena, Dora Leticia Orjuela, Jorge Ernesto Victoria, Surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs , Biomedica: Vol. 28 No. 3 (2008)
- Diana Hoyos , Rossi Meza, Liliana Forero , César Moreira, Beatriz E. Ferro, Robinson Pacheco , Treatment for RR/MDR tuberculosis: a comparative analysis of programmatic outcome indicators between Buenaventura and other municipalities of Valle del Cauca-Colombia , Biomedica: Vol. 44 No. 3 (2024): Publicación anticipada, septiembre
- Leandro Galvis, Ángel Y. Sánchez, Leonardo F. Jurado, Martha I. Murcia, Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia , Biomedica: Vol. 38 No. 1 (2018)
- Diego Chaves, Andrea Sandoval, Luis Rodríguez, Juan C. García, Silvia Restrepo, María Mercedes Zambrano, Comparative analysis of six Mycobacterium tuberculosis complex genomes , Biomedica: Vol. 30 No. 1 (2010)
- Leonardo F. Jurado, Martha I. Murcia, Patricia Hidalgo, John E. Leguizamón, Lorena R. González, Phenotypic and genotypic diagnosis of bone and miliary tuberculosis in an HIV+ patient in Bogotá, Colombia , Biomedica: Vol. 35 No. 1 (2015)
- Dihadenys Lemus, Miguel Echemendía, Raúl Díaz, Alina Llop, María Josefa Llanes, Surveillance of antituberculosis-drug resistance in Cuba, 2010-2011 , Biomedica: Vol. 34 (2014): Abril, Suplemento 1, Resistencia bacteriana
- Sonia Isabel Cuervo, Diego Andrés Bonilla, Martha Isabel Murcia, Johana Hernández, Julio César Gómez, Tuberculosis of the breast , Biomedica: Vol. 33 No. 1 (2013)
- Diana Castaño, Mauricio Rojas, Alterations in recruitment and activation of Rab proteins during mycobacterial infection , Biomedica: Vol. 30 No. 2 (2010)
- Luis F. García, Luis F. Barrera, Perspectives for new anti-tuberculous vaccines in the post-genomic era. , Biomedica: Vol. 24 (2004): Suplemento 1
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |